- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05121402
Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis
A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of TLL018 for Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis
Study Overview
Detailed Description
This is a phase 2, multicenter, randomized, double-blind, parallel dose groups, placebo-controlled dose ranging study to evaluate the safety and efficacy of 3 doses of TLL018 as an induction therapy in subjects with moderate to severe UC.
Eligible subjects will be randomized to receive one of the following treatments: TLL018 low dose, TLL018 middle dose, TLL018 high dose, or placebo. All subjects may remain on a stable dose of conventional therapy used prior to enrollment. Subjects will be assessed for safety, tolerability, and response to treatment. Samples for pharmacokinetics (PK) and pharmacodynamics (PD) biomarker analyses will be collected throughout the study according to the Schedule of Assessments (SoA) for potential correlation to clinical outcomes.
Further participation may continue beyond the initial 8 weeks for another 5-week Extension Period of therapy.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Gastroenterology Research of San Antonio (GERSA)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects ≥ 18 and ≤ 75 years of age at baseline.
- Capable of giving informed consent and complying with study procedures.
- Normal renal function or mild renal impairment as determined by the Investigator following review of clinical laboratory test results.
- Laboratory and medical history parameters within the protocol-defined ranges.
- Diagnosis of UC for 90 days or greater prior to baseline, confirmed by colonoscopy during the screening period, with exclusion of current infection, colonic dysplasia, and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.
- Active UC with a full Mayo score of 6 to 12 points and endoscopic subscore of 2 or higher confirmed by central reader.
- Subject must have received COVID-19 vaccine >2 months before first dose of study drug.
Exclusion Criteria:
- Pregnant or nursing women.
- Clinically significant history of cardiovascular, hematologic, renal, hepatic, bronchopulmonary, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator.
- Current and/or recent history of a clinically significant infection.
- Any history of malignancies, except for non-melanoma skin cancers (unless it is metastatic).
- Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
- Any condition or finding that in the Investigator's opinion would put the subjects or study conduct at risk if the subjects were to participate in the study.
- Current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC).
- Current diagnosis of fulminant colitis and/or toxic megacolon, or active Clostridium difficile colitis.
- Subject with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
- Subject with previous exposure to JAK inhibitor (eg, tofacitinib, baricitinib, filgotinib, upadacitinib).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose TLL018,BID
Drug: TLL018 all subjects will receive TLL018 for 8 weeks
|
a TYK2/JAK1 inhibitor
|
Experimental: Middle dose TLL018,BID
Drug: TLL018 all subjects will receive TLL018 for 8 weeks
|
a TYK2/JAK1 inhibitor
|
Experimental: High dose TLL018,BID
Drug: TLL018 all subjects will receive TLL018 for 8 weeks
|
a TYK2/JAK1 inhibitor
|
Placebo Comparator: Placebo
Placebo twice daily for 8 weeks.
|
a TLL018 Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects who achieved clinical remission per adapted Mayo score at Week 8
Time Frame: Baseline to Week 8
|
Baseline to Week 8
|
|
Number of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 8 weeks
|
TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
|
Up to 8 weeks
|
Incidence of Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)
Time Frame: Up to 8 weeks
|
Up to 8 weeks
|
|
Number of Participants With Clinically Significant Changes in clinical laboratory data
Time Frame: Up to 8 weeks
|
Laboratory investigation included hematology, biochemistry, urinalysis and coagulation.
Clinical significance was determined by the investigator.
The number of participants with clinically significant changes from baseline in laboratory parameters were reported.
|
Up to 8 weeks
|
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time Frame: Up to 8 weeks
|
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height.
Clinical significance was determined by the investigator.
The number of participants with clinically significant changes from baseline in vital signs were reported.
|
Up to 8 weeks
|
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings
Time Frame: Up to 8 weeks
|
Clinically significant ECG criteria included QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30<=change<60.
|
Up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of subjects with endoscopic improvement at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects with endoscopic remission at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects achieving clinical response per adapted Mayo score at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects achieving clinical response per partial adapted Mayo score at Week 2
Time Frame: Week 2
|
Week 2
|
|
Percentage of subjects who achieved histologic-endoscopic mucosal improvement (as defined by endoscopic subscore and Geboes score) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects with mucosal healing (as defined by the endoscopic and histologic variables) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects who achieved histologic improvement (as defined by Geboes score) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Percentage of subjects who reported no bowel urgency (as monitored electronically via a handheld device) at Week 8
Time Frame: Week 8
|
Week 8
|
|
Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Time Frame: Baseline to Week 8
|
The IBDQ is used to measure disease specific quality of life on a 32 Likert-scaled items questionnaire.
The IBDQ scale contains 4 component subscales: bowel symptoms, systemic symptoms, emotional function and social function with scores ranging from 10 to 70, 5 to 35, 12 to 84 and 5 to 35 respectively and the total score ranges from 32 to 224.
Higher scores indicate better health related quality of life.
|
Baseline to Week 8
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Questionnaire Score
Time Frame: Baseline to Week 8
|
The FACIT system is a collection of quality of life (QOL) questionnaires targeted to the management of cancer and other chronic illnesses.
|
Baseline to Week 8
|
Time to improvement as measured by rectal bleeding via handheld device
Time Frame: Baseline to Week 8
|
Baseline to Week 8
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TLL018-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedIntensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET (In-TARGET)ULCERATIVE COLITISFrance, Belgium
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
Clinical Trials on TLL018
-
Hangzhou Highlightll Pharmaceutical Co., LtdRecruitingPlaque PsoriasisUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompletedChronic Spontaneous UrticariaChina
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompletedModerate to Severe Plaque PsoriasisChina
-
TLL Pharmaceutical, LLCCompleted